Daniel J. Nevrivy, Ph.D.
Dr. Nevrivy counsels clients regarding the development of intellectual property strategies and patent portfolio management. He has nearly a decade of experience preparing and prosecuting cutting edge biotechnology and pharmaceutical patent applications. In particular, he has experience in stem cells and regenerative medicine, diagnostics, genomics, antibodies, inflammation, cancer, menopausal diseases, fertility, vaccines, pharmaceutical formulation and drug delivery technologies, and various therapeutic methods of treatment. He has a diverse client base, ranging from individual inventors, startup companies and universities to privately held and publicly traded corporations.
Dr. Nevrivy's practice further encompasses conducting freedom to operate, due diligence, patentability, invalidity and noninfringement investigations. In particular, he has significant experience helping companies navigate the complex patent issues associated with the development of pharmaceutical products. He has authored numerous invalidity and noninfringement opinions (in the context of impending pharmaceutical litigation) on patents covering products with sales in the hundreds of millions/billions of dollars per year.
Prior to entering law, Dr. Nevrivy conducted scientific research in the fields of molecular and cellular biology and molecular pharmacology. He investigated the role of retinoids and their effects on pluripotent embryonal carcinoma cells and he identified and characterized the function of a retinoic acid induced gene from these cells. In addition, he worked on projects relating to mechanisms of transcriptional activation and repression mediated by members of the steroid/thyroid hormone receptor superfamily, which include the retinoic acid receptors (RARs) and peroxisome proliferator-activated receptors (PPARs), among many others.
Before starting Nevrivy Patent Law Group, Dr. Nevrivy was with Sterne, Kessler, Goldstein & Fox in Washington, D.C. He provides frequent commentary and analysis regarding legal and business issues affecting the life science industry. His recent interviews and publications include:
"China gets serious about biotech," FierceBiotech
"Alkermes To Put Its Long-Acting Stamp On Trusted Blockbusters, Starting With Abilify," "The Pink Sheet," Elsevier, February 2010
"Restoring Science to its Rightful Place in America," IPLaw360
Contact Information
Phone: 202-247-6015
email: dnevrivy@nevrivylaw.com
Admissions
District of Columbia
U.S. Patent and Trademark Office
Education
J.D. George Mason University
Ph.D. Molecular and Cellular Biology, Oregon State University
B.S. Biology and B.A. Chemistry, Trinity University (TX)
Associations & Memberships
American Bar Association
American Intellectual Property Law Association
District of Columbia Bar Association
Technology Council of Maryland
MdBio
Dr. Nevrivy’s technical publications include:
Nevrivy et al. Interaction of GRASP, a protein encoded by a novel retinoic acid-induced gene, with members of the cytohesin family of guanine nucleotide exchange factors. J Biol Chem 275(22):16827-36 (2000)
Avram et al. Isolation of a novel family of C(2)H(2) zinc finger proteins implicated in transcriptional repression mediated by chicken ovalbumin upstream promoter transcription factor (COUP-TF) orphan nuclear receptors. J Biol Chem 275(14):10315-22 (2000)
Dowell et al. Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor alpha interacting protein. J Biol Chem 274(22):15901-7 (1999)
Avram et al. Heterodimeric interactions between chicken ovalbumin upstream promoter-transcription factor family members ARP1 and ear2. J Biol Chem 274(20):14331-6 (1999)
Dowell et al. p300 functions as a coactivator for the peroxisome proliferator-activated receptor alpha. J Biol Chem 272(52):33435-43 (1997)
Suite M-100 | Washington, D.C. 20007
Copyright © 2008 Nevrivy Patent Law Group P.L.L.C. All Rights Reserved. Disclaimers